lifirafenib

Lifirafenib is an investigational, orally available small molecule inhibitor targeting both monomeric and dimeric forms of RAF kinases (including BRAF, ARAF, and CRAF) as well as the epidermal growth factor receptor (EGFR). It is designed to inhibit key components of the MAPK signaling pathway implicated in tumorigenesis. Lifirafenib has demonstrated antitumor activity in preclinical models and clinical studies involving patients with solid tumors harboring mutations in BRAF (including V600E and non-V600E), KRAS, or NRAS. The drug also exhibits inhibitory activity against other kinases such as DDR1/2, EPHA3, FLT3, VEGFR2, ABL1, RET, EPHGA7/B2, MNK2, ZAK and PDGF receptors. Lifirafenib is being developed primarily for advanced or refractory solid tumors with MAPK pathway aberrations. It has been studied both as monotherapy and in combination with MEK inhibitors such as mirdametinib[2][3][4][5][6][7]. Developers: BeiGene

Other names

lifirafenibBeigene-283Beigene283Beigene 283